Published in Oncoimmunology on July 01, 2012
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 1.35
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Immunogenic cell death in radiation therapy. Oncoimmunology (2013) 1.04
Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95
Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol (2014) 0.95
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83
The Concept of Hormesis in Cancer Therapy - Is Less More? Cureus (2015) 0.82
Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol (2015) 0.78
Local immunomodulation for cancer therapy: Providing treatment where needed. Oncoimmunology (2013) 0.77
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy (2016) 0.77
Modulation of dendritic cell function by the radiation-mediated secretory protein γ-synuclein. Cell Death Discov (2015) 0.77
Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. PLoS One (2015) 0.76
Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med (2013) 0.76
TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities. Oncoimmunology (2015) 0.75
New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology (2013) 0.75
The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget (2017) 0.75
Cross-talk between tumors can affect responses to therapy. Oncoimmunology (2015) 0.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 2.80
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ (2007) 2.58
Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut (1998) 2.11
Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 1.82
An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol (1975) 1.72
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res (2008) 1.29
Abscopal regression in lymphoma: a mechanism in common with total body irradiation? Clin Radiol (1981) 1.04
Abscopal regression following radiotherapy for adenocarcinoma. Br J Radiol (1983) 1.01
Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice. Int J Oncol (2007) 0.98
Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity. Arch Dermatol (2011) 0.93
Abscopal effect on hepatocellular carcinoma. Am J Gastroenterol (2008) 0.88
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol (2004) 2.13
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev (2006) 2.00
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 1.86
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Autophagy and cellular immune responses. Immunity (2013) 1.71
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res (2009) 1.64
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis (2009) 1.56
Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev (2007) 1.55
The potential of exosomes in immunotherapy. Expert Opin Biol Ther (2005) 1.52
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. Eur J Immunol (2005) 1.46
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol (2010) 1.44
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res (2010) 1.43
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol (2006) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J (2011) 1.28
Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med (2008) 1.23
Pyroptosis - a cell death modality of its kind? Eur J Immunol (2010) 1.23
Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol (2008) 1.22
Exosomes for immunotherapy of cancer. Adv Exp Med Biol (2003) 1.22
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res (2013) 1.22
Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther (2005) 1.22
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21
Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother (2003) 1.20
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
The immunogenicity of tumor cell death. Curr Opin Oncol (2009) 1.19
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol (2012) 1.17
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res (2012) 1.16
Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci (2010) 1.16
How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev (2011) 1.15
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res (2011) 1.14
Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci (2010) 1.12
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy (2012) 1.12
NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med (2013) 1.12
Viral subversion of immunogenic cell death. Cell Cycle (2009) 1.12
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology (2012) 1.12
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09